The addition of cleanrooms is the first stage of an expansion programme that will eventually see the Glycotope increase its annual antibody production capacity at the plant from its current level of 4kg to 11kg by the end of the year.
In total the firm, which is a subsidiary of Berlin-based Glycotope, will add 1,400 sqm of manufacturing, downstream processing and office space at the facility.
Steffen Goletz, founder and CEO of Glycotope, predicted that the expansion will position the firm “among the top providers of GMP-production for recombinant proteins and in particular antibodies in Germany”.